This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
*
In these discussions, we refer to all nonanimal experiments as in vitro, regardless of the use of live bacteria and/or mammalian cells
References
Pawelek, J., Low, K. B., and Bermudes, D. (1997) Tumor-targeted Salmonella as a novel anticancer agent. Cancer Res. 57, 4537ā4544.
Low, K. B., Ittensohn, M., Le, T., et al. (1999) Lipid A mutant Salmonella with suppressed virulence and TNFĪ± induction retain tumor-targeting in vivo. Nature Biotechnol. 17, 37ā41.
Angelakopoulos, H. and Hohmann, E. L. (2000) Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 68, 2135ā41.
Cryz, S. J. Jr, Que, J. U., Levine, M. M., Wiedermann, G., and Kollaritsch, H. (1995) Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect. Immun. 63, 1336ā1339.
Dilts, D. A., Riesenfeld-Orn, I., Fulginiti, J. P., et al. (2000) Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine 18, 1473ā1484.
Gonzales, C., Hone, D., Noriega, F. R., et al. (1994) Salmonella typhi vaccine strain CVD904 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 169, 927ā931.
Hohmann, E. L., Oletta, C. A., and Miller, S. I. (1996) Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 14, 19ā24.
Hohmann, E. L., Oletta, C. A., Killeen, K. P., and Miller S. I. (1996) phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173, 1408ā1414.
Kollaritsch, H., Furer, E., Herzog, C., Wiedermann, G., Que, J. U., and Cryz, S. J., Jr. (1996) Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines. Infect. Immun. 64, 1454ā1457.
Levine, M. M., Hone, D. M., Stocker, B. A. D., and Cadoz, M. (1990) New and improved vaccines against typhoid fever, in: New Generation Vaccines, (Woodrow, G. C. and Levine, M. M., eds.), Marcel Dekker, New York, pp. 269ā287.
Levine, M. M., Ferreccio, C., Abrego, P., Martin, O. S., Ortiz, E., and Cryz, S. (1999) Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 17(Suppl. 2), S22āS27.
Tacket, C. O., Hone, D. M., Curtiss, R., III, et al. (1992) Comparson of the safety and immunogenicity of ĪaroC ĪaroD and Īcya Īcrp Salmonella typhi strains in adult volunteers. Infect. Immun. 60, 536ā541.
Tacket, C. O., Sztein, M. B., Losonsky, G. A., et al. (1997) Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65, 452ā456.
Tacket, C. O., Sztein, M. B., Wasserman, S. S., et al. (2000) Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 68, 1196ā1201.
Clairmont, C., Lee, K. C., Pike, J., et al. (2000) Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J. Infect. Dis. 181, 1996ā2002.
Lee, K. C., Zheng, L.-M., Luo, X., et al. (2000) Comparative evaluation of the acute toxic effects in monkeys, pigs, and mice of a genetically engineered Salmonella strain (VNP20009) being developed as an antitumor agent. Int. J. Toxicol. 19, 19ā25.
Davis, R. W., Botstein, D., and Roth, J. R. (1980) Advanced Bacterial Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Bermudes, D., Low, B., and Pawelek, J. (2000) Tumor-targeted Salmonella: strain development and expression of the HSV TK effector gene, in: Gene Therapy: Methods and Protocol, (Walther, W. and Stein U. eds.), Humana, Totowa, NJ, Vol. 35, pp. 419ā436.
Bochner, B. R., Huang, H-C., Schieven, G. L., and Ames, B. N. (1980) Positive selection for loss of tetracycline resistace. J. Bacteriol. 143, 926ā933.
Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Russell, C. B., Thaler, D. S., and Dalhlquist, F. W. (1989) Chromosomal transformation of Escherichia coli recD-strains with linearized plasmids. J. Bacteriol. 171, 2609ā2613.
Murray, S. R., Bermudes, D., de Felipe, K. S., and Low, K. B. (2001) Extragenic suppressors of msbB ā growth defects in Salmonella. J. Bacteriol. 183, 5554ā5561.
Donnenberg, M. S. and Kaper, J. B. (1991) Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect. Immun. 59, 4310ā4317.
GalĆ”n, J. E., Nakayama, K., and Curtiss, R., III. (1990) Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 94, 29ā35.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2004 Humana Press Inc.
About this protocol
Cite this protocol
Low, K.B. et al. (2004). Construction of VNP20009. In: Springer, C.J. (eds) Suicide Gene Therapy. Methods in Molecular Medicineā¢, vol 90. Humana Press. https://doi.org/10.1385/1-59259-429-8:47
Download citation
DOI: https://doi.org/10.1385/1-59259-429-8:47
Publisher Name: Humana Press
Print ISBN: 978-0-89603-971-1
Online ISBN: 978-1-59259-429-0
eBook Packages: Springer Protocols